

## DRUG QUANTITY MANAGEMENT POLICY – PER RX

**POLICY:** Ophthalmology – Dry Eye Disease Drug Quantity Management Policy – Per Rx

- Lacrisert® (hydroxypropyl cellulose ophthalmic insert – Bausch & Lomb)

**REVIEW DATE:** 08/19/2022

---

### OVERVIEW

Lacrisert, an ophthalmic insert made of hydroxypropyl cellulose, is indicated for the following uses:<sup>1</sup>

- **Decreased corneal sensitivity.**
- **Exposure keratitis.**
- **Moderate to severe dry eye syndromes**, including keratoconjunctivitis sicca.
- **Recurrent corneal erosions.**

Lacrisert acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states.<sup>1</sup> Lacrisert also acts to lubricate and protect the eye. Lacrisert usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision. Progressive visual deterioration which occurs in some patients may be slowed, halted, or sometimes reversed.

### Dosing

One Lacrisert ophthalmic insert placed in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes.<sup>1</sup> Individual patients may require more flexibility in the use of Lacrisert. Some patients may require twice daily use for optimal results. In some patients, several weeks may be required before satisfactory improvement of symptoms is achieved.

### Availability

Lacrisert is available as a 5 mg ophthalmic insert supplied in packages containing 60 unit doses, two reusable applicators, and a plastic storage container to store the applicators after use.<sup>1</sup>

### POLICY STATEMENT

This Drug Quantity Management program has been developed to manage potential premature dose escalation of Lacrisert. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Automation:** None.

### Drug Quantity Limits

| Product   | Strength and Form      | Retail Maximum Quantity per Rx | Home Delivery Quantity per Rx |
|---|------------------------|--------------------------------|-------------------------------|
| Lacrisert®<br>(hydroxypropyl cellulose ophthalmic insert) | 5 mg ophthalmic insert | 60 inserts                     | 180 inserts                   |

### CRITERIA

08/19/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

1. If the patient has not experienced improvement in dry eye symptoms with daily dosing, approve the requested quantity, not to exceed 120 ophthalmic inserts per dispensing at retail and 360 ophthalmic inserts per dispensing at home delivery.

Note: Examples of dry eye symptoms include conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision.

## REFERENCES

1. Lacrisert® ophthalmic insert [prescribing information]. Bridgewater, NJ: Bausch & Lomb; October 2019.